Method for the treatment of neutropenia by administration of a multi-pegylated granulocyte colony stimulating factor (g-csf) variant
EP1919498A2
Liquid factor vii composition
BRPI0611221A2
pegylated g-csf polypeptides and their production methods
EP1893230A2
Use of modified factor vii for treating bleeding
WO2005073375A1
Regulated stop codon readthrough
WO2005023308A1
Formulations of vitamin k-dependent polypeptides and sulfoalkyl ether cycloextrins
NZ587580A
Factor VII or VIIa Gla domain variants
WO2004113385A1
Protein c propeptide variants
ZA200308376B
Interferon gamma polypeptide variants.
CA2491178A1
Full-length interferon gamma polypeptide variants
BR0309576A
Factor vii (fvii) or factor viia (fviia) polypeptide variant, nucleotide sequence, expression vector, host cell, pharmaceutical composition, use of a variant, and method for treating a mammal having a disease or disorder in that clot formation is desirable
US2003133907A1
Interferon gamma polypeptide variants
NZ530545A
Specific conjugates comprising a polypeptide exhibiting G-CSF activity and a non-polypeptide moiety
US2003118612A1
G-CSF conjugates
MXPA03011793A
Interferon formulations.
ZA200204623B
G-CSF conjugates.
AU2002338313A1
Single chain dimeric polypeptides derived from the vegf family
